Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Fig. 3

Percent change from baseline in cerebrospinal fluid (CSF) and plasma amyloid-β 1–40 (Aβ1–40) at day 28 (4 h postdose) across treatment groups for Caucasian patients with early Alzheimer’s disease (AD) and Japanese patients with preclinical AD. a Caucasian early AD and Japanese preclinical AD percent change from baseline in day 28 CSF Aβ1–40. b Caucasian early AD and Japanese preclinical AD percent change from baseline in day 28 plasma Aβ1–40

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193